He leads a clinical and laboratory research programme on the prevention and treatment of cryptococcal meningitis with colleagues from St George’s, and in collaboration with other UK institutions, and colleagues across study sites in Sub-Saharan Africa. As a member of the InterTB consortium, he is also involved in phase II and III clinical trials aimed at simplifying and reducing the duration of treatment for pulmonary tuberculosis through the use of high dose rifamycins, and leads the hospital multi-drug resistant (MDR) TB service and research programme.